Clinical Trial Update: An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain [Phase 2]

View source ↗

Summary

Phase 2 open-label extension evaluating the continued efficacy and safety of escalating doses of lacosamide in adults with chronic refractory neuropathic pain; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Pain

Drugs mentioned

• Vimpat (lacosamide) (lacosamide)

Snippet

Sponsor: UCB Pharma | Conditions: Chronic Refractory Neuropathic Pain | Phase 2 | Status: COMPLETED | Results posted: 2012-05-15